Search Results
Your search for ,kEY matches 7151 pages
Showing 151 - 200Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma
In an interim analysis of a phase III trial (KEYVIBE-010) reported in The Lancet Oncology, Dummer et al found that adjuvant therapy with a coformulation of the anti-TIGIT antibody vibostolimab with pembrolizumab did not improve outcomes vs pembrolizumab alone in patients with resected high-risk...
Microplastics Found in 90% of Prostate Cancer Samples
Microplastics and nanoplastics were identified in samples from 9 out of 10 patients with prostate cancer, with greater levels of these small plastic fragments inside tumors than in nearby normal tissue, according to findings from a small pilot study that will be presented at the upcoming 2026 ASCO...
New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer
Researchers have developed a new computational approach designed to better account for changes in gene expression within tumors relative to their unique microenvironments. This approach outperformed current methods for predicting chemotherapy response in patients with triple-negative breast ...
Acral Melanoma: Ancestry and Genetics Impact Outcomes
A genetic study of Mexican patients with acral melanoma revealed that the cancer subtype encompasses three groups that may each have distinct gene expressions associated with different survival outcomes, according to findings published in Nature. “We found that acral melanoma is not a single...
Inequalities in Use of Minimally Invasive Surgical Resection in Colon Cancer
In an English population–based study reported in The Lancet Oncology, Maringe et al found that inequalities in provision of minimally invasive surgical resection of colon cancer may be associated with poorer patient outcomes. Study Details The study involved data from patients diagnosed with stage...
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
In an individual patient data meta-analysis (WOLVERINE) reported in The Lancet Oncology, Tang et al found that the addition of metastasis-directed therapy (MDT) to standard of care (SOC) was associated with benefits in patients with oligometastatic prostate cancer. Study Details A systematic review ...
Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers
In a UK study reported in the Journal of Clinical Oncology, Gandhi et al found that whereas breast cancer incidence was reduced with bilateral risk-reducing mastectomy (BRRM) among women carrying BRCA1/BRCA2 pathogenic variants, no difference vs surveillance was observed in breast cancer–specific...
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
Researchers developed a deep neural network, M-PACT, to identify and classify brain tumors in pediatric patients from the subnanogram-input cell-free DNA of methylomes, according to findings published in Nature Cancer. “This is a next-generation assay and computational framework that we’ve...
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Treatment with the novel CD123-targeting antibody-drug conjugate pivekimab sunirine led to a high rate of complete and durable responses in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially among patients being treated in the front-line setting. The antibody-drug...
Does Diabetes Increase Pancreatic Cystic Neoplasm Risk?
Longer duration of diabetes is associated with a modestly increased risk of developing pancreatic cystic neoplasms, based on the results of a Korean nationwide population-based cohort study published in JAMA Network Open. Cho et al noted that the association was more pronounced among younger...
Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer
The addition of the BRAF inhibitor encorafenib and the EGFR antibody cetuximab to chemotherapy with FOLFIRI (leucovorin, fluorouracil, and irinotecan) in the first-line treatment of BRAF V600E–mutated metastatic colorectal cancer led to a significant improvement in overall response rate—compared...
Pleurectomy/Decortication Safe in Select Patients With Pleural Mesothelioma
Pleurectomy/decortication can be completed safely in select patients with pleural mesothelioma with low postoperative mortality, according to findings from a study published in The Annals of Thoracic Surgery. “Our findings show that pleurectomy/decortication can be done safely when patients are...
Ultra-Hypofractionated vs Conventionally Fractionated RT for Localized Prostate Cancer—10-Year Outcomes
As reported in The Lancet Oncology by Nilsson et al, the 10-year analysis of the phase III HYPO-RT-PC trial confirmed the noninferiority of ultra-hypofractionated vs conventionally fractionated radiotherapy (RT) in failure-free survival in patients with localized prostate cancer. The previously...
Topline Progression-Free Survival Results From BREAKWATER in Metastatic Colorectal Cancer Newly Announced
Pfizer has announced positive topline progression-free survival results from cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating encorafenib in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated...
Can a Game-Based Intervention Reduce Cardiovascular Risk in Minority Cancer Survivors?
A remotely delivered, behaviorally designed game-based intervention was found to increase physical activity and may have implications for cardiovascular health among Black and Hispanic breast and prostate cancer survivors with cardiovascular risk factors compared with attention control, according...
Cancer Surgery Outcomes Similar Between Rural and Urban Facilities
Patients in rural areas who received surgery locally for their lung or colon cancer had comparable surgical outcomes and mortality rates to patients who underwent surgery in an urban facility, according to the results of an analysis published in the Journal of the American College of Surgeons....
COMMIT: First-Line Atezolizumab Plus FOLFOX and Bevacizumab Regimen in Metastatic Colorectal Cancer
In the phase III COMMIT trial, a regimen combining atezolizumab plus bevacizumab and standard chemotherapy significantly improved progression-free survival and response rates over atezolizumab monotherapy in patients with previously untreated mismatch repair deficient (dMMR) or microsatellite...
Computational Histology Artificial Intelligence–Powered Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer
In a study reported in the Journal of Clinical Oncology, Hendifar et al found that a computational histology artificial intelligence (CHAI)-powered platform could be used to identify whether gemcitabine-based (G-chemo) or fluoropyrimidine-based (F-chemo) chemotherapy is preferred as first-line...
Nonmetastatic Breast Cancer: Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors
Aromatase inhibitors are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen production, aromatase inhibitors can accelerate bone loss and increase fracture risk. To counter this,...
Induction Nivolumab Before CRT in High-Risk HPV-Driven Oropharyngeal Cancer
In a French phase II trial (IMMUNEBOOST-HPV) reported in the Journal of Clinical Oncology, Mirghani et al found that use of induction nivolumab prior to chemoradiation (CRT) did not meet the endpoint of ‘receipt of full treatment in due time’ (FTDT) in patients with high-risk human papillomavirus...
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive Breast Cancer
In a Chinese phase III trial (neoCARHP) reported in the Journal of Clinical Oncology, Gao et al found that neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) was noninferior in pathologic complete response (pCR) compared with THP plus carboplatin (TCbHP) in patients with stage...
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Treatment with a single injection of an oncolytic virus induces persistent T cell–mediated immunity in glioblastoma, according to findings from a trial published in Cell. “Patients with glioblastoma have not benefited from immunotherapies that have transformed patient care in other cancer types...
Demographic and Clinicopathologic Factors in Colorectal Adenoma Recurrence Risk
As reported in JAMA Network Open by Awan et al, both histopathologic and demographic factors show distinct time-dependent associations with colorectal adenoma recurrence in postpolypectomy surveillance. In this retrospective cohort study, high-grade dysplasia demonstrated the strongest association...
Young-Onset Pancreatic Cancer: Can Alcohol Consumption Raise Risk?
In a nationwide Korean cohort study reported in the Journal of Clinical Oncology, Park et al found that risk of young-onset pancreatic cancer was associated with increased consumption of alcohol and increased frequency of alcohol consumption. Study Details In the study, a nationwide cohort of...
Interval Cancer Rate With AI-Supported Mammography Screening
In a Swedish trial (MASAI) reported in The Lancet, Gommers et al found that artificial intelligence (AI)-supported mammography was noninferior to standard double reading without AI in identifying interval breast cancers in women undergoing breast cancer screening. Study Details In the study,...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib...
GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting
As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive...
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
As reported in the Journal of Clinical Oncology by Tung et al, findings in expansion cohorts of the phase II Translational Breast Cancer Research Consortium (TBCRC) 048 study showed that olaparib was active in patients with metastatic breast cancer with germline PALB2 mutations (gPALB2m) and in...
A New Risk Model for Esophagectomy Draws on the STS National Database
A nationwide, real-world analysis using the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) from 2012 to 2023 evaluated over 16,000 adults who underwent esophagectomy for primary esophageal cancer to develop and validate a long-term all-cause mortality risk model. The...
Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors
In an Indian single-center phase III trial (DELII) reported in the Journal of Clinical Oncology, Noronha et al found that “ultra–low-dose” immune checkpoint inhibitor therapy with the PD-1 inhibitor nivolumab was associated with improved overall survival vs standard chemotherapy among patients with ...
Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors
In a phase III single-blind randomized clinical trial reported in JAMA Network Open, Zick et al found that self-acupressure—taught via a mobile app—provided a safe, low-cost approach for managing fatigue in ovarian cancer survivors. “In this randomized clinical trial, true self-acupressure and sham ...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
HPV Testing During Cervical Cancer Screening: Potential ‘Convenient and Noninvasive’ Method
Testing menstrual blood for human papillomavirus (HPV) could be a “robust alternative or replacement” for current cervical cancer screening by a clinician, according to findings from a Chinese study published by Tian et al in The BMJ. The researchers say using menstrual blood for HPV testing is...
Tissue-Free ctDNA and Outcomes in Patients With Colorectal Cancer Receiving FOLFOX-Based Adjuvant Therapy
In a study reported in the Journal of Clinical Oncology, Sinicrope et al found that a tissue-free circulating tumor DNA (ctDNA) assay had strong prognostic value in patients receiving FOLFOX (fluorouracil, leucovorin, and oxaliplatin)-based adjuvant therapy for stage III colorectal cancer. Study...
Ultraprocessed Food Associated With Increased Mortality Risk in Cancer Survivors
Consumption of higher quantities of ultraprocessed food was associated with increased all-cause and cancer mortality rates in cancer survivors, irrespective of the quality of their diet, according to findings published in Cancer Epidemiology, Biomarkers & Prevention. “These results suggest...
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
The U.S. Food and Drug Administration (FDA) has provided communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil—indicated for colorectal, breast, gastric/esophageal/gastroesophageal, and pancreatic cancers—related to risks associated...
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Willems et al, venous thromboembolism (VTE) occurred in a high proportion of patients with resectable/borderline resectable pancreatic ductal adenocarcinoma receiving neoadjuvant FOLFOXIRI (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin)...
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
Exposure to Agent Orange in U.S. veterans was associated with an increased odds of developing acral melanoma compared with controls with and without cutaneous melanoma, according to findings published in JAMA Dermatology. The study authors suggested that there is a need for continued investigation ...
New European Project Cluster EARLYSCAN Launched to Advance Early Detection of Heritable Cancers
A new European collaboration cluster, EARLYSCAN (Early Screening & Hereditary Cancer Awareness Network), has been launched to strengthen prevention and early detection strategies for heritable cancers. The cluster brings together three Horizon Europe–funded projects: SHIELD, DISARM, and...
First-Line mFOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Conca et al, the final results of the Italian phase III TRIPLETE trial showed that first-line mFOLFOXIRI (modified fluorouracil, leucovorin, oxaliplatin, irinotecan) plus panitumumab improved overall survival vs mFOLFOX (modified fluorouracil,...
Metastasis-Directed Therapy for Oligometastatic Prostate Cancer
Metastasis-directed therapy significantly improved progression-free survival, radiologic progression–free survival, and castration resistance–free survival in patients with oligometastatic prostate cancer, according to a new study published by Tang et al in The Lancet Oncology. The study is a...
WHO Analysis Finds Nearly 40% of Global Cancer Cases Attributable to Modifiable Risk Factors
Almost 40% of all new cancer cases could be attributed to at least one of 30 modifiable risk factors, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The analysis of preventable cancers was published in Nature...
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
In a phase III trial (PATINA) reported in The New England Journal of Medicine, Metzger et al found that the addition of palbociclib to anti-HER2 and endocrine therapies significantly prolonged progression-free survival in patients with hormone receptor–positive, HER2-positive metastatic breast...
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
AI Tool May Predict Cardiac Events in Patients With Cancer and Acute Coronary Syndrome
An artificial intelligence (AI)-based risk prediction model, ONCO-ACS, showed possible favorable clinical utility as a practical tool for predicting cardiovascular death, myocardial infarction, and ischemic stroke events in patients with cancer and acute coronary syndrome, according to findings...
Overall Survival With 3 vs 6 Months of Adjuvant Oxaliplatin Plus Fluoropyrimidine for Colorectal Cancer
As reported in the Journal of Clinical Oncology by Iveson et al, final results of the UK-based noninferiority phase III SCOT trial have shown noninferiority of 3 vs 6 months of adjuvant oxaliplatin plus fluoropyrimidine chemotherapy in overall survival among patients with colorectal cancer....
Adjuvant Aumolertinib in EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhang et al, the Chinese phase III ARTS trial showed superior disease-free survival with the third-generation EGFR tyrosine kinase inhibitor aumolertinib as adjuvant therapy vs placebo in patients with completely resected stage II to IIIB EGFR-mutated non–small ...
